Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet — RxCUI 1375948
RxNorm drug concept · Semantic clinical drug
RxCUI 1375948
Semantic clinical drug · SCD
● Current RxNorm concept 7 FDA products
8 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1375948
Official nameDoxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdoxylamine succinate 10 MG / vit-B6 Hydrochloride 10 MG Delayed Release Oral Tablet; doxylamine succinate 10 MG / pyridoxine HCl 10 MG Delayed Release Oral Tablet; doxylamine succinate 10 MG / vitamin B6 Hydrochloride 10 MG Delayed Release Oral Tablet
FDA products mapped7
Package NDCs mapped8
Reported Medicaid activity (SDUD)86,071 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Doxylamine and Pyridoxine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Yes — this is the only FDA-approved oral medication specifically indicated for nausea and vomiting of pregnancy. Multiple large studies, including meta-analyses covering tens of th...
- Is this medication actually safe to take during pregnancy?
- Food can significantly reduce how much of the pyridoxine (vitamin B6) component your body actually absorbs — in some studies by around 50%. It also delays when the medication start...
- Why do I have to take it on an empty stomach?
🕸️ Concept Web — How Doxylamine succinate 10 MG / pyridoxine hydrochl... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet
RxCUI 1375948 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 5
The active substance itself — no strength, form, or brand attached yet.
-
Doxylamine
3642IN -
Pyridoxine
684879IN -
Doxylamine / pyridoxine
1375947MIN -
Doxylamine succinate
23665PIN -
Pyridoxine hydrochloride
203164PIN
-
Doxylamine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Diclegis
1375949BN
-
Diclegis
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Doxylamine / pyridoxine Delayed Release Oral Tablet
1375946SCDF -
Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet
2648926SCDFP -
Doxylamine / pyridoxine Oral Product
1375944SCDG -
Doxylamine / pyridoxine Pill
1375945SCDG -
Doxylamine succinate / pyridoxine hydrochloride Oral Product
2659428SCDGP -
Doxylamine succinate / pyridoxine hydrochloride Pill
2662894SCDGP -
Doxylamine / pyridoxine Delayed Release Oral Tablet [Diclegis]
1375951SBDF -
Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet [Diclegis]
2657734SBDFP - +5 more in this family
-
Doxylamine / pyridoxine Delayed Release Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Doxylamine succinate 10 MG
1242514SCDC -
Pyridoxine hydrochloride 10 MG
349805SCDC -
Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis]
1375954SBD -
Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG [Diclegis]
1375950SBDC
-
Doxylamine succinate 10 MG
Showing up to 8 concepts per family — 18 of 23 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Doxylamine succinate 10 MG
SCDC · 1242514 -
Pyridoxine hydrochloride 10 MG
SCDC · 349805 -
Doxylamine / pyridoxine Delayed Release Oral Tablet
SCDF · 1375946 -
Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet
SCDFP · 2648926 -
Doxylamine / pyridoxine Oral Product
SCDG · 1375944 -
Doxylamine / pyridoxine Pill
SCDG · 1375945 -
Doxylamine succinate / pyridoxine hydrochloride Oral Product
SCDGP · 2659428 -
Doxylamine succinate / pyridoxine hydrochloride Pill
SCDGP · 2662894
Brand-Name Concepts
-
Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG Delayed Release Oral Tablet [Diclegis]
SBD · 1375954 -
Doxylamine succinate 10 MG / pyridoxine hydrochloride 10 MG [Diclegis]
SBDC · 1375950 -
Doxylamine / pyridoxine Delayed Release Oral Tablet [Diclegis]
SBDF · 1375951 -
Doxylamine succinate / pyridoxine hydrochloride Delayed Release Oral Tablet [Diclegis]
SBDFP · 2657734 -
Diclegis Oral Product
SBDG · 1375952 -
Diclegis Pill
SBDG · 1375953 -
Diclegis
BN · 1375949
📦 FDA Products & Package NDCs
7 products · 8 package NDCs
8 package NDCs map to RxCUI 1375948 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00591-2132-01 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (0591-2132-01) | Doxylamine succinate and pyridoxine hydrochloride | Actavis Pharma, Inc. | 2019-06-21 |
| 49884-0186-01 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (49884-186-01) | Doxylamine Succinate and Pyridoxine Hydrochloride | Endo USA, Inc. | 2019-12-19 |
| 55494-0100-10 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (55494-100-10) | DICLEGIS | Duchesnay USA, Inc. | 2013-05-15 |
| 55494-0100-99 | 12 TABLET, DELAYED RELEASE in 1 BOTTLE (55494-100-99) | DICLEGIS | Duchesnay USA, Inc. | 2014-03-28 |
| 63629-2184-01 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (63629-2184-1) | Doxylamine Succinate and Pyridoxine Hydrochloride | Bryant Ranch Prepack | 2021-03-12 |
| 69452-0206-20 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (69452-206-20) | Doxylamine succinate and Pyridoxine hydrochloride | Bionpharma Inc., | 2023-12-11 |
| 70505-0100-10 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (70505-100-10) | Doxylamine succinate and pyridoxine hydrochloride | Analog Pharma | 2018-11-15 |
| 72162-1485-01 | 100 TABLET, DELAYED RELEASE in 1 BOTTLE (72162-1485-1) | Doxylamine Succinate and Pyridoxine Hydrochloride | Bryant Ranch Prepack | 2023-08-30 |
Observed labelers:
Bryant Ranch Prepack (2) ·
Duchesnay USA, Inc. (2) ·
Actavis Pharma, Inc. (1) ·
Analog Pharma (1) ·
Bionpharma Inc., (1) ·
Endo USA, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.2494
Range $1.2494–$1.6776
· middle 50% $1.2494–$1.2494
· 5 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.